TKNO Q2 2025 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena

TKNOAlpha Teknova, Inc.

$133M

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$10M+7.0% YoY

Gross Profit

$4M38.7% margin

Operating Income

-$3M-32.9% margin

Net Income

-$4M-34.7% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+5.0%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$950,000

Balance Sheet

Total Assets

$110M

Total Liabilities

$34M

Stockholders' Equity

$76M

Cash & Equivalents

$3M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$10M	+7.0%
Gross Profit	$4M	$3M	+42.1%
Operating Income	-$3M	-$5M	+33.6%
Net Income	-$4M	-$5M	+33.4%

Revenue Segments

Lab Essentials

$8M76%

Clinical Solutions

$2M20%

Other Product

$435,0004%

Geographic Segments

UNITED STATES

$10M95%

Non-US

$510,0005%